NSE: CORONA · BSE: 544644 · ISIN INE02ZQ01018
CORONA Remedies Limited stock analysis
CORONA Remedies Limited ranks #54 in the TickerSutra evidence-ranked universe with a score of 75/100 and 91% data confidence. The latest captured fundamentals show ROCE of 33.3%, quarterly sales growth of 21.9% and quarterly profit growth of 29.5%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 33.3%
- Low debt/equity of 0.22×
- 16.6% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹617cr | ₹18cr | ₹0cr | 2.9% |
| 2023 | ₹884cr | ₹128cr | ₹85cr | 14.0% |
| 2024 | ₹1,014cr | ₹156cr | ₹90cr | 15.0% |
| 2025 | ₹1,196cr | ₹241cr | ₹149cr | 20.0% |
| 2026 | ₹1,403cr | ₹294cr | ₹185cr | 21.0% |
| TTM | ₹1,479cr | ₹317cr | ₹199cr | 21.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
CORONA Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineCorona Remedies Ltd - 544644 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011BSE · 19 Sept 2026The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sepia Investments Ltd, Sage Investment Trust ....
RoutineCorona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationBSE · 18 Sept 2026Intimation of participation in Analyst / Investor meet
RoutineCorona Remedies Ltd - 544644 - Clarification On Movement In VolumeBSE · 10 Sept 2026Reply to Clarification
RoutineCorona Remedies Ltd - 544644 - Clarification sought from Corona Remedies LtdBSE · 10 Sept 2026The Exchange has sought clarification from Corona Remedies Ltd on September 10, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
MANAGEMENT COMMENTARY
Signals from filed documents
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…